Priority Lists
Protocol Posting of
Activations
Activation
A Comparative Randomized Study of Standard Doxorubicin And Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin And Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory And Locally Advanced Breast Cancer
| Study Coordinator(s) | Georgiana K. Ellis, M.D., Robert B. Livingston, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Pathologists, EPP, CTSU |
Activation
Docetaxel and Vinorelbine Plus Filgrastim for HER-2 Negative, Stage IV Breast Cancer, Phase II
| Study Coordinator(s) | Julie R. Gralow, M.D., Robert B. Livingston, M.D. |
| Participants | Members, NCORP |
Activation
A Phase II Study of Flavopiridol (NSC-649890) 1 Hour Bolus Days 1-3 Q 21 Days in Patients with Advanced Renal Cell Cancer
| Study Coordinator(s) | Peter J. Van Veldhuizen, M.D., Primo N. Lara, Jr., M.D., Paul H. Gumerlock, Ph.D. |
| Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons, Pathologists |
Closures
Permanent Closure (effective 5/15/01)
A Phase III Study of Interferon-Refractory Patients with BCR/ABL (+) Chronic Myelogenous Leukemia (CML) Treated with Homoharringtonine (NSC-141633) Vs. Hydroxurea
| Study Coordinator(s) | Harry P. Erba, M.D.,Ph.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Pathologists, NCORP, Members |
| Closure Date | 2001-05-15 |
Permanent Closure: effective 6/1/01
Pilot Study of l-Selenomethionine in Prostate Cancer Patients Scheduled to Undergo Radical Prostatectomy
| Study Coordinator(s) | Anita L. Sabichi, M.D., Ian M. Thompson Jr., M.D., Brian J. Miles, M.D. |
| Closure Date | 2001-06-01 |
Amendments, Revisions, Memoranda
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation for Patients with Untreated Acute Promyelocytic Leukemia
| Action Codes | ER |
| Study Coordinator(s) | Steven E. Coutre, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Pathologists, NCORP, Members |
Randomized Phase III Trial of ABVD Versus Stanford V +/- Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin’s Disease with 0-2 Risk Factors
| Study Coordinator(s) | Richard I. Fisher, M.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Pathologists, NCORP |
A Phase III Study of Flt3 Ligand (Flt3L) (NSC #696599) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission
| Study Coordinator(s) | John E. Godwin, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Members, NCORP |
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Overexpressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Surgeons |
Revision #6
Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma
| Study Coordinator(s) | Lawrence E. Flaherty, M.D., John A. Thompson, M.D., Ralph J. Tuthill, M.D., John Vetto, M.D., Vernon K. Sondak, M.D., Jeffrey A. Sosman, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, ECOG, COG, US INSTITUTIONS ONLY |
Revision #1
Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer
| Study Coordinator(s) | Raja Mudad, M.D., FACP, Laurie E. Gaspar, M.D., R. Chapman, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
Evaluation of ZD 1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II
| Study Coordinator(s) | Daniel P. Petrylak, M.D., Peter J. Van Veldhuizen, M.D. |
| Participants | Members, NCORP, UCOP, Medical Oncologists, Surgeons, Pathologists |
Revision #1
A Phase II Study of PN401, 5-FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach.
| Study Coordinator(s) | James H. Doroshow, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP |
Amendment #1
Lung Cancer Specimen Repository Protocol, Ancillary
| Study Coordinator(s) | Wilbur A. Franklin, M.D., Paul H. Gumerlock, Ph.D., David R. Gandara, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, NCIC-CTG, ECOG |
Revision #3
Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes, Phase III
| Study Coordinator(s) | Lori J. Pierce, M.D. |
| Participants | Medical Oncologists, Radiation Oncologists, Surgeons, NCCTG, RTOG, ACOSOG, ECOG, CALGB, NCORP, Members, NCIC-CTG, NSABP |
Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II
| Study Coordinator(s) | Louis E. Schroder, M.D., Mario A. Eisenberger, M.D., Daniel J. Culkin, M.D. |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required